United Community Bank Has $2.41 Million Stake in Johnson & Johnson $JNJ

United Community Bank reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 30.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,009 shares of the company’s stock after selling 5,807 shares during the quarter. Johnson & Johnson accounts for 0.7% of United Community Bank’s portfolio, making the stock its 28th largest position. United Community Bank’s holdings in Johnson & Johnson were worth $2,412,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently modified their holdings of JNJ. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson in the second quarter valued at about $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. boosted its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth $35,000. Finally, Signature Resources Capital Management LLC raised its position in shares of Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after acquiring an additional 184 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Loop Capital set a $220.00 price objective on Johnson & Johnson in a research note on Tuesday, January 27th. Leerink Partners raised their target price on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $250.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Sunday, January 25th. Finally, Wolfe Research boosted their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $233.05.

Johnson & Johnson Trading Up 1.6%

NYSE JNJ opened at $230.82 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock’s 50-day moving average is $211.21 and its 200-day moving average is $192.24. Johnson & Johnson has a one year low of $141.50 and a one year high of $231.19. The firm has a market cap of $556.11 billion, a P/E ratio of 20.89, a P/E/G ratio of 2.21 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business had revenue of $24.56 billion during the quarter, compared to analysts’ expectations of $24.14 billion. During the same period in the prior year, the business earned $2.04 EPS. Johnson & Johnson’s revenue for the quarter was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.